Experts tip very big returns from these outstanding ASX 200 blue chip shares

These two shares are arguably among the best the market has to offer.

| More on:
Contented looking man leans back in his chair at his desk and smiles.

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The benchmark ASX 200 index is home to 200 of the largest listed companies on the Australian share market.

While not all shares on the index will necessarily be good portfolio additions (i.e. Weebit Nano Ltd ASX:WBT) ), two that could be are listed below.

These are two true blue chip stars and have been tipped to deliver strong returns for investors in 2024. They are as follows:

CSL Limited (ASX: CSL)

The first ASX 200 blue chip share for investors to look at is biotherapeutics giant CSL.

It is arguably one of Australia's highest quality companies, developing life-saving therapies and vaccines for the global population. Among its portfolio are products such as Albumex, Privigen, Hizentra, Idelvion, and Afstyla.

But it won't stop there. CSL reinvests in the region of 12% of its sales revenue back into research and development (R&D) each year. This means the company has an R&D pipeline filled with some potentially lucrative (and life-saving) therapies and vaccines.

The team at Morgans rates the company highly. Its analysts have an add rating and $328.20 price target on its shares. This implies potential upside of almost 14% for investors from current levels.

ResMed Inc. (ASX: RMD)

Another quality ASX 200 blue chip share that is highly rated by analysts is ResMed.

It is one of the world's leading sleep treatment companies with a portfolio of products for sufferers of disorders such as sleep apnoea.

This certainly is a lucrative market to be in. The company estimates that one in five people has a sleep disorder globally, with the vast majority still undiagnosed. And while weight loss drugs could steal a share of this market, most analysts agree that there's still a huge addressable market for ResMed to grow into over the next couple of decades.

It is partly for this reason that Macquarie has an outperform rating and $33.40 price target on its shares. This suggests upside of almost 27% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

3 excellent ASX 200 blue chip shares to buy in 2025

Analysts have good things to say about these blue chips.

Read more »

A fit man flexes his muscles, indicating a positive share price movement on the ASX market
Blue Chip Shares

3 strong ASX 200 blue chip stocks to buy with $2,000 in December

These blue chips have been given the thumbs up from analysts.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Blue Chip Shares

Analysts name 3 strong blue chip ASX 200 shares to buy in December

Let's see which blue chips are bring tipped as buys by analysts right now.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Blue Chip Shares

Buy these 3 high-quality ASX 200 blue chip shares in December

Analysts think these high-quality shares are buys right now. Let's see what they are saying.

Read more »

Two people comparing and analysing material.
Blue Chip Shares

Are Woodside or CBA shares a better buy?

Here’s how I’d compare these two major ASX blue chips.

Read more »

A group of young people lined up on a wall are happy looking at their laptops and devices as they invest in the latest trendy stock.
Blue Chip Shares

Why these ASX 200 blue chip shares could generate big returns

Brokers think these shares are could be dirt cheap at current levels.

Read more »

Man sits smiling at a computer showing graphs
Blue Chip Shares

3 ASX shares Australians can buy and hold for the next decade

Analysts think these high quality stocks could be in the buy zone right now.

Read more »

2 women looking at phone
Blue Chip Shares

3 high quality blue chip ASX 200 shares to buy in November

Here are a few blue chip shares that have been rated as buys this month by analysts.

Read more »